A-022 A pilot study evaluating NT-proBNP and hs-cTnI levels in pneumoconiosis patients with and without cardiovascular diseases

Q He
DOI: https://doi.org/10.1093/clinchem/hvae106.022
IF: 12.114
2024-10-27
Clinical Chemistry
Abstract:BackgroundPneumoconiosis is a serious occupational lung disease in China that is progressive and irreversible but lacks systematic research. This pilot case-control study was conducted to understand levels of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI) in pneumoconiosis patients with and without cardiovascular diseases.MethodsPneumoconiosis patients with/without cardiovascular diseases were recruited from the West China Occupational Pneumoconiosis Cohort in West China Fourth Hospital. Healthy controls were adults who underwent health check-ups and matched by age with the pneumoconiosis patients at the same hospital. The serum concentrations of NT-proBNP and hs-cTnI were measured by the automated QuidelOrthoTM VitrosTM 5600 system from July 2023 to January 2024. The levels of NT-proBNP and hs-cTnI between the two groups were compared by the Mann-Whitney U test.ResultsAmong 105 male pneumoconiosis patients in our analysis, 63 reported cardiovascular diseases with a median age of 71(61,75) years and 42 without cardiovascular diseases with a median age of 65.5 (58,76) years, with no statistically significant difference (p=0.386). The median NT-proBNP level was 211(102,432)pg/mL for pneumoconiosis with cardiovascular diseases and 104(39.6,190) pg/mL for pneumoconiosis without cardiovascular diseases, the difference beingstatistically significant (p<0.001). The median hs-cTnI level was 2.14(1.50,4.25)ng/L for pneumoconiosis with cardiovascular diseases and 1.50(1.50, 1.52)ng/L for pneumoconiosis without cardiovascular diseases, the difference being statistically significant (p<0.001). Patients who had pneumoconiosis with pulmonary heart diseases had the highest NT-proBNP and hs-cTnI levels,(summarized in Table 1). There was no significant difference in the levels of NT-proBNP and hs-cTnI between patients who had pneumoconiosis without cardiovascular diseases and 65 healthy control participants.ConclusionsThe incident rate of cardiovascular diseases among pneumoconiosis patients is significantly higher than in the general population, especially pulmonary heart diseases. Future studies are needed to evaluate the levels of NT-proBNP and hs-cTnI in individuals with pneumoconiosis at diagnosis and over time.
medical laboratory technology
What problem does this paper attempt to address?